Cantor Fitzgerald Weighs in on NTLA FY2026 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Intellia Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Bienkowski anticipates that the company will post earnings of ($3.05) per share for the year. The consensus estimate for Intellia Therapeutics' current full-year earnings is ($5.07) per share.

A number of other research analysts have also recently weighed in on NTLA. The Goldman Sachs Group restated a "sell" rating and issued a $9.00 price target on shares of Intellia Therapeutics in a research report on Friday, February 28th. Chardan Capital reissued a "buy" rating and issued a $68.00 price objective on shares of Intellia Therapeutics in a research note on Friday, May 9th. Wedbush restated a "neutral" rating and set a $7.00 target price (down from $10.00) on shares of Intellia Therapeutics in a report on Thursday, May 29th. Guggenheim reduced their price target on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating on the stock in a report on Monday, May 12th. Finally, Canaccord Genuity Group lowered their price target on shares of Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating on the stock in a research report on Tuesday, June 3rd. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Intellia Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $34.95.

Intellia Therapeutics Stock Performance

NTLA stock traded down $0.04 during midday trading on Tuesday, hitting $8.31. 3,282,892 shares of the stock were exchanged, compared to its average volume of 2,812,570. The stock's 50-day moving average price is $8.05 and its 200-day moving average price is $9.91. The stock has a market cap of $860.77 million, a price-to-earnings ratio of -1.53 and a beta of 2.14. Intellia Therapeutics has a fifty-two week low of $5.90 and a fifty-two week high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.26) by $0.16. The firm had revenue of $16.63 million for the quarter, compared to analysts' expectations of $11.39 million. Intellia Therapeutics's revenue was down 42.6% compared to the same quarter last year. During the same period last year, the firm earned ($1.12) EPS.

Institutional Investors Weigh In On Intellia Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Ensign Peak Advisors Inc lifted its position in Intellia Therapeutics by 2.9% during the fourth quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company's stock worth $457,000 after buying an additional 1,100 shares during the period. HighTower Advisors LLC increased its stake in shares of Intellia Therapeutics by 8.2% during the 1st quarter. HighTower Advisors LLC now owns 16,921 shares of the company's stock valued at $120,000 after acquiring an additional 1,282 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Intellia Therapeutics by 14.0% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company's stock valued at $157,000 after acquiring an additional 1,582 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of Intellia Therapeutics by 6.1% during the 4th quarter. Arizona State Retirement System now owns 28,006 shares of the company's stock worth $327,000 after acquiring an additional 1,615 shares during the period. Finally, E Fund Management Co. Ltd. boosted its position in shares of Intellia Therapeutics by 10.0% in the fourth quarter. E Fund Management Co. Ltd. now owns 18,053 shares of the company's stock worth $210,000 after acquiring an additional 1,634 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company's stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.